Back to results
US 6,187,748 B1Granted
Uses of CD4-gamma2 and CD4-IgG2 chimeras
AssigneeProgenics Pharmaceuticals, Inc.
InventorsPaul J. Maddon, Gary A. Beaudry
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeProgenics Pharmaceuticals, Inc.
InventorsPaul J. Maddon, Gary A. Beaudry
Estimating the term…
This invention provides the CD4-IgG2 chimeric heterotetramer, wherein the heavy chains of the chimeric heterotetramer is encoded by the expression vector designated CD4-IgG2HC-pRcCMV (ATCC No. 75193). This invention also provides the CD4-IgG2 chimeric heterotetramer, wherein the light chains of the chimeric heterotetramer is encoded by the expression vector designated CD4-kLC-pRcCMV (ATCC No. 75194). This invention also provides the CD4-IgG2 chimeric heterotetramer, wherein the heavy chains of the chimeric heterotetramer is encoded by the expression vector designated CD4-IgG2HC-pRcCMV (ATCC No. 75193) and the light chains of the chimeric heterotetramer is encoded by the expression vector designated CD4-kLC-pRcCMV (ATCC No. 75194). Finally, this invention provides a method of inhibiting HIV infection of a CD4+ cell, a method of preventing a subject from being infected with HIV, and a method of treating a subject infected with HIV so as to block the spread of HIV infection, using the above CD-4-IgG2 chimeric heterotetramers.
A method of inhibiting infection of a CD4+ cell by a human immunodeficiency virus which comprises contacting the human immunodeficiency virus with an amount of a CD4-IgG2 chimeric heterotetramer effective to form a complex with all such human immunodeficiency virus which is in the presence of the CD4+ cell so as to thereby inhibit infection of the CD4+ cell by the virus, wherein the CD4-IgG2 chimeric heterotetramer comprises two heavy chains and two light chains, the heavy chains being encoded by an expression vector designated CD4-IgG2HC-pRcCMV (ATCC No. 75193) and the light chains being encoded by an expression vector designated CD4-kLC-pRcCMV (ATCC No. 75194).
A method of preventing CD4+ cells of a subject from becoming infected with human immunodeficiency virus which comprises administering to the subject an amount of a CD4-IgG2 chimeric heterotetramer effective to bind to any human immunodeficiency virus present in the subject, so as to thereby prevent the subject's CD4+ cells from becoming infected with human immunodeficiency virus, wherein the CD4-IgG2 chimeric heterotetramer comprises two heavy chains and two light chains, the heavy chains being encoded by an expression vector designated CD4-IgG2HC-pRcCMV (ATCC No. 75193) and the light chains being encoded by an expression vector designated CD4-kLC-pRcCMV (ATCC No. 75194).
A method of treating a subject having CD4+ cells infected with human immunodeficiency virus which comprises administering to the subject an amount of a CD4-IgG2 chimeric heterotetramer effective to bind to any human immunodeficiency virus present in the subject, so as to thereby treat the subject having CD4+ cells infected with human immunodeficiency virus, wherein the CD4-IgG2 chimeric heterotetramer comprises two heavy chains and two light chains, the heavy chains being encoded by an expression vector designated CD4-IgG2HC-pRcCMV (ATCC No. 75193) and the light chains being encoded by an expression vector designated CD4-kLC-pRcCMV (ATCC No. 75194).
Dependencies are inferred from the claim text.